Literature DB >> 21278714

End-stage renal disease in 2010: Innovative approaches to improve outcomes in transplantation.

Ron Shapiro1.   

Abstract

Renal transplantation offers the potential for improved quality and length of life to patients with end-stage renal disease; however, graft rejection and immunosuppression-related toxicities can hamper the effectiveness of this therapy. Seminal publications from 2010 have addressed these obstacles, and provide insight into new and innovative approaches to improve outcomes in renal transplant recipients.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21278714     DOI： 10.1038/nrneph.2010.179

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  6 in total

1.  Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.

Authors:  R Carlin Walsh; Jason J Everly; Paul Brailey; Adele H Rike; Lois J Arend; Gautham Mogilishetty; Amit Govil; Prabir Roy-Chaudhury; Rita R Alloway; E Steve Woodle
Journal:  Transplantation       Date:  2010-02-15       Impact factor: 4.939

2.  A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).

Authors:  A Durrbach; J M Pestana; T Pearson; F Vincenti; V D Garcia; J Campistol; M del Carmen Rial; S Florman; A Block; G Di Russo; J Xing; P Garg; J Grinyó
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

3.  A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors:  F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

4.  Pancreas after living donor kidney versus simultaneous pancreas-kidney transplant: an analysis of the organ procurement transplant network/united network of organ sharing database.

Authors:  Neda Poommipanit; M S Sampaio; Yong Cho; Brian Young; Tariq Shah; Phuong-Thu Pham; Alan Wilkinson; Gabriel Danovitch; Suphamai Bunnapradist
Journal:  Transplantation       Date:  2010-06-27       Impact factor: 4.939

5.  Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial.

Authors:  R Salgo; J Gossmann; H Schöfer; H G Kachel; J Kuck; H Geiger; R Kaufmann; E H Scheuermann
Journal:  Am J Transplant       Date:  2010-02-01       Impact factor: 8.086

6.  Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies.

Authors:  R Sberro-Soussan; J Zuber; C Suberbielle-Boissel; S Candon; F Martinez; R Snanoudj; M Rabant; N Pallet; D Nochy; D Anglicheau; M Leruez; A Loupy; E Thervet; O Hermine; C Legendre
Journal:  Am J Transplant       Date:  2010-02-01       Impact factor: 8.086
  6 in total
  9 in total

1.  Circulating lymphocyte subsets in different clinical situations after renal transplantation.

Authors:  Pablo J E J van de Berg; Eveline C Hoevenaars; Si-La Yong; Karlijn A M I van Donselaar-van der Pant; Anne van Tellingen; Sandrine Florquin; René A W van Lier; Fréderike J Bemelman; Ineke J M ten Berge
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

2.  CD28 family and chronic rejection: "to belatacept...And beyond!".

Authors:  Marcos V Silva; Juliana R Machado; Laura P Rocha; Lúcio R Castellano; Marlene A Reis; Rosana R M Corrêa
Journal:  J Transplant       Date:  2012-06-07

3.  Immune response following liver transplantation compared to kidney transplantation: usefulness of monitoring peripheral blood CD4+ adenosine triphosphate activity and cytochrome P450 3A5 genotype assay.

Authors:  Yu Nobuoka; Shugo Mizuno; Kouhei Nishikawa; Kaname Nakatani; Yuichi Muraki; Tomomi Yamada; Masahiro Okuda; Tsutomu Nobori; Yoshiki Sugimura; Shuji Isaji
Journal:  Clin Dev Immunol       Date:  2013-12-25

Review 4.  Live kidney donation: are concerns about long-term safety justified?-A methodological review.

Authors:  Shiromani Janki; Ewout W Steyerberg; Albert Hofman; Jan N M IJzermans
Journal:  Eur J Epidemiol       Date:  2016-06-28       Impact factor: 8.082

5.  Clinical relevance of a CD4+ T cell immune function assay in the diagnosis of infection in pediatric living-donor liver transplantation.

Authors:  Wei Liu; Kai Wang; Yi-He Zhao; Guang-Ping Song; Wei Gao; Dai-Hong Li
Journal:  Exp Ther Med       Date:  2019-09-13       Impact factor: 2.447

6.  Immunological aspects in late phase of living donor liver transplant patients: usefulness of monitoring peripheral blood CD4+ adenosine triphosphate activity.

Authors:  Shugo Mizuno; Yuichi Muraki; Kaname Nakatani; Akihiro Tanemura; Naohisa Kuriyama; Ichiro Ohsawa; Yoshinori Azumi; Masashi Kishiwada; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata; Norihiko Yamamoto; Tomomi Yamada; Katsuya Shiraki; Yoshiyuki Takei; Tsutomu Nobori; Masahiro Okuda; Shuji Isaji
Journal:  Clin Dev Immunol       Date:  2013-09-26

7.  LOng-term follow-up after liVE kidney donation (LOVE) study: a longitudinal comparison study protocol.

Authors:  Shiromani Janki; Karel W J Klop; Hendrikus J A N Kimenai; Jacqueline van de Wetering; Willem Weimar; Emma K Massey; Abbas Dehghan; Dimitris Rizopoulos; Henry Völzke; Albert Hofman; Jan N M Ijzermans
Journal:  BMC Nephrol       Date:  2016-02-01       Impact factor: 2.388

8.  Peripheral blood CD4(+) cell ATP activity measurement to predict HCC recurrence post-DCD liver transplant.

Authors:  W Zhang; H Zhong; L Zhuang; J Yu; X Xu; W Wang; M Zhang; L Zhou; S Zheng
Journal:  Int J Clin Pract       Date:  2016-06       Impact factor: 2.503

9.  Robotic assisted nephrectomy for living kidney donation (RANLD) with use of multiple locking clips or ligatures for renal vascular closure.

Authors:  Maximilian Brunotte; Sebastian Rademacher; Justine Weber; Elisabeth Sucher; Andri Lederer; Hans-Michael Hau; Jens-Uwe Stolzenburg; Daniel Seehofer; Robert Sucher
Journal:  Ann Transl Med       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.